## RPD: Rapid7, Inc. - XLK: Technology

### Executive Summary

VALUE thesis: PEG 0.29 indicates fundamental undervaluation. Quality metrics strong (ROE 37%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-4.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($14.36)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($3.90M) |
| Sells | 6 ($0.36M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 13.2% (+7.4%)
- Blackrock Inc.: 10.1% (-1.1%)
- Jana Partners Manage: 9.9% (+13.5%)
- UBS Group AG: 4.9% (-28.9%)
- Penserra Capital Man: 4.1% (-1.8%)

### Key Risks

1. Long-term trend broken: trading 26.8% below SMA200.
2. Falling knife pattern: rapid decline without stabilization, catch risk elevated.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.29 indicates undervaluation relative to growth. Quality metrics strong (ROE 37%). Insider buying signal ($3.9M), management confidence. Institutional flow bearish (5 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $1.0B |
| Beta | 0.84 |
| 52W Range | $13.21 - $41.38 |
| Short Interest | 7.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.29 |
| Forward P/E | 7.8 |
| Current P/E | 7.5 |
| YoY Growth | -2.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.4% to -2.2% (-4.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >4.0% for momentum thesis). Below SMA200 (0.73x), long-term trend not supportive. RSI neutral at 45. Elevated volume (2.0x 20MA), institutional activity likely. OFD pattern: =DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.20% (CS: 25) | Weak |
| RSI_14 | 45.3 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 0.954x | Below |
| vs SMA200 | 0.732x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $15.50
- **Stop Loss:** $14.36 (7.4% risk)
- **Target:** $17.78 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1052
- **Position Value:** $16,306.00
- **Portfolio %:** 16.31%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-11 (Est: $0.42)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.46 | $0.57 | +24.9% |
| 2025Q2 | $0.44 | $0.58 | +30.9% |
| 2025Q1 | $0.34 | $0.49 | +42.3% |
| 2024Q4 | $0.50 | $0.48 | -3.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*